Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mexiletine
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Recipient : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin and Avas Launch NaMuscla in Italy
Details : NaMuscla (mexiletine hydrochloride) is a Sodium channel alpha subunit blocker, being evaluated for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.
Product Name : Namuscla
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Mexiletine
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Recipient : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
